One patient with brain cancer and another with liver cancer survived more than five years without recurrence after receiving personalized cancer vaccines.

The firm is restructuring to extend its cash runway and focus resources on clinical programs, including a Phase I CAR T-cell trial in kidney cancer.

A real-world study showed that patients who had the classical subtype based on an RNA signature had better survival on ...

The firm, which so far has focused on cancer, expects to file an IND application for a treatment for tyrosinemia type I and alkaptonuria next year.

After the deal closes, Biogen will be in charge of developing and selling Alcyone's ThecaFlex DRx implantable subcutaneous port and catheter device.